Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships
Lunai Bioworks (NASDAQ:RENB) announced progress in its biomarker discovery preclinical program for Parkinson's Disease through its subsidiary BioSymetrics. The company's Augusta Platform leverages AI and machine learning to identify distinct patient subtypes and uncover novel treatment pathways.
The initiative addresses a significant market opportunity, with Parkinson's affecting over 10 million people globally and expected to double by 2050. BioSymetrics' Phenograph knowledge graph enables patient stratification and therapeutic hypothesis matching, supported by an NIH STTR grant. The company is actively seeking pharmaceutical partnerships to advance its biomarker-driven programs.
Lunai Bioworks (NASDAQ:RENB) ha annunciato progressi nel suo programma preclinico di scoperta di biomarcatori per la malattia di Parkinson tramite la sua controllata BioSymetrics. La piattaforma Augusta dell'azienda utilizza IA e apprendimento automatico per identificare sottotipi di pazienti distinti e scoprire nuovi percorsi di trattamento.
L'iniziativa affronta una significativa opportunità di mercato, con la malattia di Parkinson che colpisce oltre 10 milioni di persone in tutto il mondo e si prevede che raddoppierà entro il 2050. Il grafo di conoscenza Phenograph di BioSymetrics consente la stratificazione dei pazienti e l'abbinamento di ipotesi terapeutiche, supportato da una sovvenzione NIH STTR. L'azienda è attivamente in cerca di partnership farmaceutiche per avanzare i suoi programmi guidati dai biomarcatori.
Lunai Bioworks (NASDAQ:RENB) anunció avances en su programa preclínico de descubrimiento de biomarcadores para la enfermedad de Parkinson a través de su subsidiaria BioSymetrics. La plataforma Augusta de la empresa utiliza IA y aprendizaje automático para identificar distintos subtipos de pacientes y descubrir nuevos caminos terapéuticos.
La iniciativa aborda una oportunidad de mercado significativa, con la enfermedad de Parkinson afectando a más de 10 millones de personas en todo el mundo y se espera que se duplique para 2050. El grafo de conocimiento Phenograph de BioSymetrics permite la estratificación de pacientes y la coincidencia de hipótesis terapéuticas, respaldado por una sovvenión NIH STTR. La empresa está buscando activamente asociaciones farmacéuticas para impulsar sus programas basados en biomarcadores.
Lunai Bioworks (NASDAQ:RENB)가 자회사 BioSymetrics를 통해 파킨슨병 바이오마커 발견의 전임상 프로그램에서 진전을 발표했습니다. 회사의 Augusta Platform는 인공지능과 기계학습을 활용해 환자 하위군을 구분하고 새로운 치료 경로를 발견합니다.
이 이니셔티브는 시장 기회를 크게 개척합니다. 전 세계적으로 파킨슨병은 1,000만 명 이상에 영향을 미치며 2050년까지 두 배로 증가할 것으로 예상됩니다. BioSymetrics의 Phenograph 지식 그래프는 환자 계층화와 치료 가설 매칭을 가능하게 하며, NIH STTR 보조금의 지원을 받습니다. 회사는 바이오마커 기반 프로그램을 진전시키기 위해 제약 파트너십을 적극 모색 중입니다.
Lunai Bioworks (NASDAQ:RENB) a annoncé des progrès dans son programme préclinique de découverte de biomarqueurs pour la maladie de Parkinson, via sa filiale BioSymetrics. La plateforme Augusta de l'entreprise utilise l'IA et l'apprentissage automatique pour identifier des sous-types de patients distincts et découvrir de nouvelles voies thérapeutiques.
L'initiative répond à une opportunité de marché importante, la maladie de Parkinson touchant plus de 10 millions de personnes dans le monde et devrait doubler d'ici 2050. Le graphe de connaissances Phenograph de BioSymetrics permet la stratification des patients et l'appariement d'hypothèses thérapeutiques, soutenu par une subvention NIH STTR. L'entreprise recherche activement des partenariats pharmaceutiques pour faire progresser ses programmes basés sur les biomarqueurs.
Lunai Bioworks (NASDAQ:RENB) kündigte Fortschritte in seinem pränklichen Programm zur Biomarker-Entdeckung bei Parkinson über die Tochtergesellschaft BioSymetrics an. Die Augusta-Plattform des Unternehmens nutzt KI und maschinelles Lernen, um verschiedene Patientensubtypen zu identifizieren und neuartige Behandlungswege aufzudecken.
Die Initiative eröffnet eine bedeutende Marktchance, wobei Parkinson weltweit mehr als 10 Millionen Menschen betrifft und bis 2050 voraussichtlich verdoppeln wird. BioSymetrics' Phenograph-Wissensgraph ermöglicht die Patientenselektion und das Matching therapeutischer Hypothesen, unterstützt durch eine NIH STTR-Förderung. Das Unternehmen sucht aktiv nach pharmazeutischen Partnerschaften, um seine biomarkergetriebenen Programme voranzutreiben.
Lunai Bioworks (NASDAQ:RENB) أعلنت عن تقدم في برنامجها قبل السريري لاكتشاف المؤشرات البيولوجية لمرض باركنسون عبر شركتها التابعة BioSymetrics. منصة Augusta الخاصة بالشركة تستخدم الذكاء الاصطناعي وتعلم الآلة لتحديد أنماط مرضى مميزة والكشف عن مسارات علاجية جديدة.
تتعامل المبادرة مع فرصة سوقية كبيرة، حيث ينطبق مرض باركنسون على أكثر من 10 ملايين شخص حول العالم ويتوقع أن يتضاعف حتى عام 2050. يتيح مخطط المعرفة Phenograph من BioSymetrics تصنيف المرضى ومطابقة فرضيات علاجية، مدعوماً بـ منحة NIH STTR. تسعى الشركة بنشاط إلى شراكات مع شركات الأدوية لدفع برامجها المعتمدة على المؤشرات الحيوية إلى الأمام.
Lunai Bioworks（纳斯达克：RENB） 通过其子公司 BioSymetrics 在帕金森病生物标志物发现的前临床计划中取得进展。公司的 Augusta 平台 利用人工智能和机器学习来鉴别不同的患者亚型并揭示新的治疗途径。
该计划处于重要的市场机会之中，帕金森病全球受影响者超过1000万人，预计到2050年将翻倍。BioSymetrics 的 Phenograph 知识图谱实现患者分层与治疗假设匹配，并得到一项 NIH STTR 资助 的支持。公司正在积极寻求制药伙伴关系，以推动其以生物标志物驱动的程序前进。
- Targeting large and growing market with over 10 million Parkinson's patients globally
- Received competitive NIH STTR grant validation
- Proprietary Augusta Platform and Phenograph technology for patient stratification
- Positioning for pharmaceutical partnerships to accelerate development
- Early-stage preclinical program with no immediate revenue potential
- Operating in highly competitive AI drug discovery space
- Significant time and resources required for drug development
Insights
Lunai advances Parkinson's biomarker program to identify drug targets and patient subtypes, positioning for pharma partnerships in a growing neurological market.
Lunai Bioworks (NASDAQ:RENB) has announced the advancement of its preclinical biomarker discovery program for Parkinson's Disease, leveraging its subsidiary BioSymetrics' Augusta Platform. The company is now actively positioning this program for pharmaceutical partnerships, which represents a potential value-creation milestone in their pipeline development.
The market opportunity is substantial, with over 10 million people affected by Parkinson's globally. This patient population is projected to double by 2050, creating a significant and growing addressable market. In the US alone, nearly one million individuals currently live with the disease.
What distinguishes Lunai's approach is their focus on phenogrouping - using their Phenograph knowledge graph and machine learning to identify distinct patient subtypes with greater precision. This stratification capability is particularly valuable in neurological disorders where treatment response varies significantly between patients. By uncovering hidden disease mechanisms and matching subgroups with targeted therapeutic hypotheses, Lunai is applying a precision medicine approach to a traditionally challenging therapeutic area.
The company's capabilities have received external validation through a competitive STTR grant from the National Institutes of Health, supporting their translational pipeline. Additionally, their work was recently highlighted in a Michael J. Fox Foundation webinar, suggesting recognition within the Parkinson's research community.
While this announcement doesn't include financial projections or partnership terms, it signals progression in Lunai's preclinical pipeline and positions the company to potentially secure valuable pharmaceutical collaborations, which typically include upfront payments, research funding, and milestone payments that could strengthen their financial position.
NEW YORK CITY, NEW YORK / ACCESS Newswire / September 25, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery company and parent of wholly owned subsidiary BioSymetrics, today announced advancement of its biomarker discovery preclinical program in Parkinson's Disease. The initiative leverages BioSymetrics' proprietary Augusta Platform to unlock novel treatment pathways in one of the world's fastest-growing neurological markets. The company is actively positioning the program for strategic partnership with pharmaceutical collaborators.
Parkinson's Disease affects over 10 million people globally, with incidence expected to double by 2050. Nearly one million individuals in the US alone live with the disease, a figure projected to rise sharply due to an aging population. This expanding patient population represents a significant unmet need and a compelling opportunity for therapeutic innovation.
BioSymetrics' approach centers on phenogrouping, identifying distinct patient subtypes using its Phenograph knowledge graph and machine learning engine. This enables the company to stratify patients with greater precision, uncover hidden disease mechanisms, and match subgroups with targeted therapeutic hypotheses. The strategy was recently spotlighted in a Michael J. Fox Foundation webinar hosted by BioSymetrics.
BioSymetrics has developed algorithms and digital biomarkers that can be applied for diagnosis, patient stratification, and treatment response prediction, as well as to accelerate therapeutic development. Its applied AI projects have used large-scale datasets to refine Parkinson's subtypes for precision medicine applications. As Lunai's wholly owned subsidiary, BioSymetrics' Parkinson's initiative spans drug target discovery, validation, and clinical study optimization.
"Our goal is to translate computational insights into actionable biology," said Dr. Gabe Musso, Chief Scientific Officer of BioSymetrics. "By integrating multimodal data and refining phenotypic subtypes, we're laying the groundwork for biomarker-driven programs that can be rapidly advanced through pharma collaboration."
BioSymetrics also contributes open-source repositories and collaborative pipelines for multimodal Parkinson's data analysis, reinforcing Lunai's commitment to both research and clinical progress. The Parkinson's initiative builds on Lunai's broader mission to integrate AI-powered analytics with translational research, accelerating diagnosis and drug discovery across complex neurological disorders.
The company's differentiated model, which combines proprietary neurotoxicity datasets, experimental screening, and machine learning, has earned validation through a competitive STTR grant from the National Institutes of Health (NIH), supporting its translational pipeline.
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. Through its wholly owned subsidiary BioSymetrics, Lunai integrates proprietary datasets, advanced machine learning, and ethical innovation to accelerate therapeutic breakthroughs while safeguarding society from emerging threats.
Investor Contact
David Weinstein
Chief Executive Officer
investors@renovaro.com
www.renovarogroup.com
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire
FAQ
What is Lunai Bioworks' (NASDAQ:RENB) approach to Parkinson's Disease research?
How many people are affected by Parkinson's Disease globally according to Lunai Bioworks?
What validation has Lunai Bioworks (RENB) received for its technology?
What is BioSymetrics' role in Lunai Bioworks' Parkinson's research?
What are Lunai Bioworks' (NASDAQ:RENB) plans for partnerships?
